Study of the Native Outflow Tract Transcatheter Pulmonary Valve (TPV)



Status:Active, not recruiting
Conditions:Peripheral Vascular Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:Any
Updated:10/20/2018
Start Date:October 2012
End Date:May 2020

Use our guide to learn which trials are right for you!

Native Outflow Tract Transcatheter Pulmonary Valve Research Clinical Study

The purpose of this early feasibility study is to determine how a new transcatheter pulmonary
valve will move and perform once implanted in the right ventricular outflow tract.

Medtronic, Inc. is in the process of developing a novel transcatheter device option for
patients with congenital heart disease, without right ventricle-to-pulmonary artery conduits,
called the Native Outflow Tract Transcatheter Pulmonary Valve. Given limitations in the
animal model to confirm device boundary conditions, this feasibility study is proposed to
characterize that information as well as evaluate safety, procedural feasibility and
performance data to be used for future development of the device.

Inclusion Criteria:

- Subject has pulmonary regurgitation as per one or more of the following criteria:
Severe pulmonary regurgitation as measured by Doppler echocardiography, or Pulmonary
regurgitant fraction ≥ 30% as measured by cardiac magnetic resonance imaging

- Clinical indication for surgical placement of a RVOT conduit or bioprosthetic
pulmonary valve per one or more of the following criteria: Subject is symptomatic
secondary to pulmonary insufficiency (e.g. exercise intolerance, fluid overload) as
classified by the Investigator, or Right ventricular end diastolic volume (RVEDV) ≥
150 ml/m2

- Subject is willing to consent to participate in the study and will commit to
completion of all follow-up requirements

Exclusion Criteria:

- Anatomy unable to accommodate a 25 Fr delivery system

- Obstruction of the central veins

- Clinical or biological signs of infection including active endocarditis

- Indicated for intervention of stenosis of the branch pulmonary arteries at time of
implant

- Positive pregnancy test at baseline (prior to CT angiography and again prior to
implant procedure) in female subjects of child bearing potential

- Patients with right ventricular outflow tract obstruction (RVOTO) lesions surgically
treated with a right ventricle-to-pulmonary artery conduit implant

- A major or progressive non-cardiac disease (e.g. liver failure, renal failure, cancer)
that results in a life expectancy of less than one year

- Planned implantation of the Native Outflow Tract TPV in the left heart

- RVOT anatomy or morphology that is unfavorable for anchoring

- Known allergy to aspirin, heparin, or nickel

- Echocardiographic evidence of intracardiac mass, thrombus, or vegetation

- Pre-existing prosthetic heart valve or prosthetic ring in any position

- Patient is currently enrolled in another investigational device or drug trial that may
influence the outcome of this trial.
We found this trial at
3
sites
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
555 University Avenue
Toronto, Ontario M5G 1X8
?
mi
from
Toronto,
Click here to add this to my saved trials